Sutro Biopharma, Inc.
STRO
$40.91
$1.604.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.65M | 9.69M | 63.75M | 17.40M | 14.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.65M | 9.69M | 63.75M | 17.40M | 14.81M |
| Cost of Revenue | 36.64M | 39.85M | 38.33M | 51.60M | 71.04M |
| Gross Profit | -25.00M | -30.16M | 25.42M | -34.20M | -56.23M |
| SG&A Expenses | 8.66M | 8.74M | 10.34M | 13.27M | 9.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.30M | 48.59M | 48.67M | 64.87M | 80.07M |
| Operating Income | -33.66M | -38.90M | 15.08M | -47.47M | -65.26M |
| Income Before Tax | -46.84M | -56.86M | -11.52M | -75.97M | -70.09M |
| Income Tax Expenses | -82.00K | -- | -18.00K | -- | 2.36M |
| Earnings from Continuing Operations | -46.76M | -56.86M | -11.50M | -75.97M | -72.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.76M | -56.86M | -11.50M | -75.97M | -72.44M |
| EBIT | -33.66M | -38.90M | 15.08M | -47.47M | -65.26M |
| EBITDA | -32.03M | -37.00M | 16.98M | -45.57M | -63.39M |
| EPS Basic | -5.35 | -6.70 | -1.36 | -9.14 | -8.56 |
| Normalized Basic EPS | -3.04 | -3.48 | 0.51 | -4.13 | -5.17 |
| EPS Diluted | -5.35 | -6.70 | -1.36 | -9.14 | -8.56 |
| Normalized Diluted EPS | -3.04 | -3.48 | 0.51 | -4.13 | -5.17 |
| Average Basic Shares Outstanding | 8.73M | 8.49M | 8.46M | 8.31M | 8.47M |
| Average Diluted Shares Outstanding | 8.73M | 8.49M | 8.46M | 8.31M | 8.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |